Table 6.
Univariate and multivariate logistic regression analyses for the secondary composite outcome
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95% CIs) | p | OR (95% CIs) | p | |
| Male sex | 1.198 (0.674–2.131) | 0.538 | 1.421 (0.714–2.831) | 0.317 |
| Age at diagnosis | 1.014 (0.995–1.034) | 0.156 | 1.005 (0.978–1.032) | 0.732 |
| Preexisting hypertension | 2.048 (1.189–3.528) | 0.010 | 1.402 (0.708–2.776) | 0.332 |
| Preexisting diabetes mellitus | 1.193 (0.539–2.639) | 0.664 | - | - |
| Percentage of sclerotic glomeruli | 1.015 (0.997–1.034) | 0.094 | 1.010 (0.990–1.031) | 0.336 |
| Moderate or severe interstitial fibrosis | 1.709 (0.682–4.285) | 0.253 | - | - |
| Moderate or severe tubular atrophy | 1.398 (0.522–3.746) | 0.505 | - | - |
| Baseline hemoglobin | 0.863 (0.751–0.991) | 0.037 | 0.843 (0.715–0.993) | 0.041 |
| Baseline eGFR | 0.992 (0.984–1.001) | 0.075 | 1.002 (0.990–1.014) | 0.775 |
| Baseline serum albumin | 0.758 (0.515–1.115) | 0.159 | - | - |
| Baseline proteinuria | 1.000 (1.000–1.000) | 0.936 | - | - |
| Use of cyclophosphamide | 0.971 (0.559–1.689) | 0.918 | - | - |
| Use of calcineurin inhibitors | 0.956 (0.554–1.649) | 0.870 | - | - |
| Use of rituximab | 1.959 (0.901–4.259) | 0.090 | 1.723 (0.746–3.977) | 0.203 |
| Use of glucocorticoid monotherapy | 1.186 (0.652–2.157) | 0.577 | - | - |
CI Confidence interval, eGFR Estimated glomerular filtration rate, OR Odds ratio